Very interesting article North....and specifically this line :
"Payers typically cover NCCN-listed uses for cancer drugs, even if they’re not specifically approved by the FDA, and this would allow doctors to go ahead and prescribe the regimen."
I wonder now, since Peregrine has NCCN on PS Targeting....why Merck needs approval from NCCN
About 7 p.m. yesterday, Dew posted on the BTValue board that MRK had a strong case for NCCN endorsement or acceptance of its request in the situation reported in the article I reported yesterday.
One of the 3 trials that NCCN selected for trial also involves Keytruda with Bavi for treatment of certain disease state. How about both companies asking NCCN to conduct trials of that combination therapy in yet other disease conditions. Funding to be provided. Same or related clinical investigator at same or different NCCN facility(out of the 26) to be involved. Instant communication back and forth.
Is the above how the clinical trial process will evolve? Just a thought.
News 
Market Data 
Discover 
